Optiscan Initiates Head and Neck Cancer Study in the US
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Optiscan Imaging Limited has announced the initiation of a new study focused on head and neck cancer in the U.S., in collaboration with Mayo Clinic. The study aims to evaluate the performance of Optiscan’s InVue™ and InForm™ imaging platforms during surgical procedures for head and neck cancer patients. Patient recruitment for the study is currently underway, with findings intended to support U.S. FDA regulatory submissions for both devices later in the year. This initiative represents a significant step in expanding the application of Optiscan's technology in complex surgical settings.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Story so far
Earlier from Optiscan Imaging
- Preliminary Final Report
- Appendix 4G & Corporate Governance Statement
- 2026 Annual Report
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Signs New Research Agreement for Breast Study
Later from Optiscan Imaging
- Change of Director's Interest Notice
- Application for quotation of securities - OIL
- Significant Milestone Reached in ACL Digital Pathology Study
- Notification of cessation of securities - OIL
- Optiscan Lodges U.S. FDA 510(k) Submission for InForm
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging